Pacira BioSciences (PCRX) EPS (Weighted Average and Diluted) (2010 - 2026)

Pacira BioSciences' EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at $0.07 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 30.0% year-over-year to $0.07; the TTM figure through Mar 2026 stood at $0.12 (up 105.29% YoY), while the FY2025 annual figure was $0.16, up 107.44% from the prior year.
• EPS (Weighted Average and Diluted) was $0.07 for Q1 2026 at Pacira BioSciences, up from $0.04 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.52 in Q4 2023 to a low of -$3.11 in Q3 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.05 across 5 years, with a median of $0.12 in 2025.
• The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) jumped 1250.0% in 2023, then plunged 1452.17% in 2024.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.22 in 2022, then soared by 336.36% to $0.52 in 2023, then tumbled by 32.69% to $0.35 in 2024, then sank by 88.57% to $0.04 in 2025, then soared by 75.0% to $0.07 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.07 (Q1 2026), $0.04 (Q4 2025), and $0.12 (Q3 2025), per Business Quant data.